Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

Objective: Ketamine has demonstrated rapid antidepressant effects in patients with
treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this …

BackgroundKetamine has been demonstrated to improve depressive symptoms.
AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients …

Introduction: Few studies have been published to date exploring the effectiveness of
ketamine for treatment-resistant depression (TRD) in large clinical samples. We report on …

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

BACKGROUND: A single subanesthetic (intravenous) IV dose of ketamine might have rapid
but transient antidepressant effects in patients with treatment-resistant depression (TRD) …

Background Due to unmet clinical needs for efficient drugs with a rapid onset of
antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different …

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-
resistant depression. Different strategies have been proposed to prolong these effects …

Background Ketamine is reported to have rapid antidepressant effects; however, there is
limited understanding of the time-course of ketamine effects beyond a single infusion. A …